BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am. 2015;44:717-734. [PMID: 26600216 DOI: 10.1016/j.gtc.2015.07.003] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 14.4] [Reference Citation Analysis]
Number Citing Articles
1 Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394:1451-1466. [PMID: 31 DOI: 10.1016/s0140-6736(19)32320-7] [Cited by in Crossref: 108] [Cited by in F6Publishing: 56] [Article Influence: 2.3] [Reference Citation Analysis]
2 Jülicher P, Galli C. Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting. J Med Econ 2018;21:1-10. [PMID: 28881157 DOI: 10.1080/13696998.2017.1369983] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
3 Sepulveda-Crespo D, Resino S, Martinez I. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs 2021;81:419-43. [PMID: 33400242 DOI: 10.1007/s40265-020-01458-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C Virus Infection: Host⁻Virus Interaction and Mechanisms of Viral Persistence. Cells 2019;8:E376. [PMID: 31027278 DOI: 10.3390/cells8040376] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
5 Vergara M, Miquel M, Vela E, Cleries M, Pontes C, Prat A, Rué M. Use of healthcare resources and drug expenditure before and after treatment of chronic hepatitis C with direct antiviral agents. J Viral Hepat 2021;28:728-38. [PMID: 33555102 DOI: 10.1111/jvh.13479] [Reference Citation Analysis]
6 Giuffrè M, Fouraki S, Comar M, Masutti F, Crocè LS. The Importance of Transaminases Flare in Liver Elastography: Characterization of the Probability of Liver Fibrosis Overestimation by Hepatitis C Virus-Induced Cytolysis. Microorganisms 2020;8:E348. [PMID: 32121404 DOI: 10.3390/microorganisms8030348] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
7 Chappell CA, Krans EE. Hepatitis C virus among pregnant women and children in the USA: an emerging epidemic. Future Virology 2018;13:855-62. [DOI: 10.2217/fvl-2018-0147] [Reference Citation Analysis]
8 Roger S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, Lunel F. HCV virology and diagnosis. Clin Res Hepatol Gastroenterol 2021;45:101626. [PMID: 33636428 DOI: 10.1016/j.clinre.2021.101626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Yu L, Xu F, Gao L. Predict New Therapeutic Drugs for Hepatocellular Carcinoma Based on Gene Mutation and Expression. Front Bioeng Biotechnol 2020;8:8. [PMID: 32047745 DOI: 10.3389/fbioe.2020.00008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
10 Lim HK, Jeffrey GP, Ramm GA, Soekmadji C. Pathogenesis of Viral Hepatitis-Induced Chronic Liver Disease: Role of Extracellular Vesicles. Front Cell Infect Microbiol 2020;10:587628. [PMID: 33240824 DOI: 10.3389/fcimb.2020.587628] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Hall EW, Rosenberg ES, Sullivan PS. Estimates of state-level chronic hepatitis C virus infection, stratified by race and sex, United States, 2010. BMC Infect Dis 2018;18:224. [PMID: 29769036 DOI: 10.1186/s12879-018-3133-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
12 Diotaiuti P, Mancone S, Falese L, Ferrara M, Bellizzi F, Valente G, Corrado S, Misiti F. Intention to Screen for Hepatitis C Among University Students: Influence of Different Communicative Scenarios. Front Psychiatry 2022;13:873566. [DOI: 10.3389/fpsyt.2022.873566] [Reference Citation Analysis]
13 Buggisch P, Heiken H, Mauss S, Weber B, Jung MC, Görne H, Heyne R, Hinrichsen H, Hidde D, König B, Pires Dos Santos AG, Niederau C, Berg T. Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study. PLoS One 2021;16:e0250833. [PMID: 33970940 DOI: 10.1371/journal.pone.0250833] [Reference Citation Analysis]
14 Barooah P, Saikia S, Kalita MJ, Bharadwaj R, Sarmah P, Bhattacharyya M, Goswami B, Medhi S. IL-10 Polymorphisms and Haplotypes Predict Susceptibility to Hepatocellular Carcinoma Occurrence in Patients with Hepatitis C Virus Infection from Northeast India. Viral Immunol 2020;33:457-67. [PMID: 32352886 DOI: 10.1089/vim.2019.0170] [Reference Citation Analysis]
15 Kotha S, Neong S, Patel K. Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. Expert Rev Mol Diagn 2018;18:713-22. [PMID: 30019978 DOI: 10.1080/14737159.2018.1496020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
16 Stevenson TJ, Barbour Y, McMahon BJ, Townshend-Bulson L, Hewitt AM, Espera HGF, Homan C, Holck P, Luna SV, Knall C, Simons BC. Observed Changes in Natural Killer and T cell Phenotypes with Evaluation of Immune Outcome in a Longitudinal Cohort Following Sofosbuvir-Based Therapy for Chronic Hepatitis C Infection. Open Forum Infect Dis 2019;6:ofz223. [PMID: 31249845 DOI: 10.1093/ofid/ofz223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
17 Mazur WP. Management of Hepatitis C in Delaware Prisons: : Approaching Microenvironmental Eradication. Dela J Public Health 2019;5:20-7. [PMID: 34467026 DOI: 10.32481/djph.2019.05.006] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Rao H, Wu E, Fu S, Yang M, Feng B, Lin A, Fei R, Fontana RJ, Lok AS, Wei L. The higher prevalence of truncal obesity and diabetes in American than Chinese patients with chronic hepatitis C might contribute to more rapid progression to advanced liver disease. Aliment Pharmacol Ther 2017;46:731-40. [PMID: 28833342 DOI: 10.1111/apt.14273] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
19 Page K, Yu M, Cohen J, Evans J, Shumway M, Riley ED. HCV screening in a cohort of HIV infected and uninfected homeless and marginally housed women in San Francisco, California. BMC Public Health. 2017;17:171. [PMID: 28173785 DOI: 10.1186/s12889-017-4102-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
20 Danilau D, Litvinchuk D, Solovey N, Krasko O, Karpov I. Association of TNF-α and CCL5 with response to interferon-based therapy in patients with HCV 1 genotype. Clin Exp Hepatol 2017;3:16-22. [PMID: 28856285 DOI: 10.5114/ceh.2017.65279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Nagra N, Kozarek RA, Burman BE. Therapeutic Advances in Viral Hepatitis A–E. Adv Ther. [DOI: 10.1007/s12325-022-02070-z] [Reference Citation Analysis]
22 Xu Y, Xue W, Gao H, Cui J, Zhao L, You C. Association of toll-like receptors single nucleotide polymorphisms with HBV and HCV infection: research status. PeerJ 2022;10:e13335. [DOI: 10.7717/peerj.13335] [Reference Citation Analysis]
23 Mate-Cano I, Alvaro-Meca A, Ryan P, Resino S, Briz V. Epidemiological trend of hepatitis C-related liver events in Spain (2000-2015): A nationwide population-based study. Eur J Intern Med 2020;75:84-92. [PMID: 32143898 DOI: 10.1016/j.ejim.2020.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
24 Njiomegnie GF, Read SA, Fewings N, George J, McKay F, Ahlenstiel G. Immunomodulation of the Natural Killer Cell Phenotype and Response during HCV Infection. J Clin Med. 2020;9. [PMID: 32268490 DOI: 10.3390/jcm9041030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
25 Sepulveda-Crespo D, Resino S, Martinez I. Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants. Vaccines (Basel) 2020;8:E313. [PMID: 32560440 DOI: 10.3390/vaccines8020313] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
26 Rehm J, Patra J, Brennan A, Buckley C, Greenfield TK, Kerr WC, Manthey J, Purshouse RC, Rovira P, Shuper PA, Shield KD. The role of alcohol use in the aetiology and progression of liver disease: A narrative review and a quantification. Drug Alcohol Rev 2021. [PMID: 33783063 DOI: 10.1111/dar.13286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Avramovic G, Oprea C, Surey J, Story A, Macías J, Cullen W, Iglesias M, Mc Hugh T, Crowley D, Naughton AM, Horan A, Ianache I, Lazar S, Popa I, Menezes D, Lambert JS. HepCare Europe-A service innovation project. HepCheck: Characteristics of the patient population with active infection as defined by HCV RNA. Int J Infect Dis 2020;91:246-51. [PMID: 31785401 DOI: 10.1016/j.ijid.2019.11.027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
28 Hatcher EL, Zhdanov SA, Bao Y, Blinkova O, Nawrocki EP, Ostapchuck Y, Schäffer AA, Brister JR. Virus Variation Resource - improved response to emergent viral outbreaks. Nucleic Acids Res 2017;45:D482-90. [PMID: 27899678 DOI: 10.1093/nar/gkw1065] [Cited by in Crossref: 137] [Cited by in F6Publishing: 104] [Article Influence: 22.8] [Reference Citation Analysis]
29 de Bitencorte JT, Rech TF, Lunge VR, dos Santos DC, Álvares-da-Silva MR, Simon D. Association of interferon lambda-4 rs12979860 polymorphism with hepatocellular carcinoma in patients with chronic hepatitis C infection. World J Hepatol 2021; 13(1): 109-119 [PMID: 33584990 DOI: 10.4254/wjh.v13.i1.109] [Reference Citation Analysis]
30 Garrido-estepa M, Latasa P, Flores-herrera J, García Comas L. Hepatitis C and hepatitis C-related advanced liver disease hospitalisation trends before and after the Strategic Plan for Tackling Hepatitis C in the National Health System. European Journal of Gastroenterology & Hepatology 2021;33:1307-15. [DOI: 10.1097/meg.0000000000001841] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Martin EF. Paradigm Shift in Utilization of Livers from Hepatitis C-Viremic Donors into Hepatitis C Virus-Negative Patients. Clin Liver Dis 2021;25:195-207. [PMID: 33978579 DOI: 10.1016/j.cld.2020.08.009] [Reference Citation Analysis]
32 Kumar S, Deo SV, Altarabsheh SE, Dunlay SM, Sarabu N, Sareyyupoglu B, Elgudin Y, Medalion B, Elamm C, Ginwalla M, Zacharias M, Benatti R, Oliveira GH, Kilic A, Fonarow GC, Park SJ. Effect of Hepatitis C Positivity on Survival in Adult Patients Undergoing Heart Transplantation (from the United Network for Organ Sharing Database). The American Journal of Cardiology 2016;118:132-7. [DOI: 10.1016/j.amjcard.2016.04.023] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
33 Cowan EA, Dinani A, Brandspiegel S, O'Brien-Lambert C, Zaheer J, Eiting E, Loo G, Calderon Y. Nontargeted Hepatitis C Screening in an Urban Emergency Department in New York City. J Emerg Med 2021;60:299-309. [PMID: 33213988 DOI: 10.1016/j.jemermed.2020.09.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Resino S, Fernández-Rodríguez A, Pineda-Tenor D, Gómez-Moreno AZ, Sánchez-Ruano JJ, Artaza-Varasa T, Muñoz-Gómez MJ, Virseda-Berdices A, Martín-Vicente M, Martínez I, Jiménez-Sousa MA. TRPM5 rs886277 Polymorphism Predicts Hepatic Fibrosis Progression in Non-Cirrhotic HCV-Infected Patients. J Clin Med 2021;10:483. [PMID: 33525598 DOI: 10.3390/jcm10030483] [Reference Citation Analysis]
35 Biciuşcă V, Popescu M, Petrescu IO, Stan IS, Durand P, Petrescu M, Velea R, Traşcă DM, Popescu IAS, Udriştoiu I, Mărginean CM, Tudoraşcu DR, Petrescu F. Hepatic pathological features in naïve patients with chronic hepatitis C who have developed thyroid disorder. Rom J Morphol Embryol 2020;61:1085-97. [PMID: 34171058 DOI: 10.47162/RJME.61.4.11] [Reference Citation Analysis]
36 Miotto N, Mendes LC, Zanaga LP, Goncales ES, Lazarini MS, Pedro MN, Goncales FL Jr, Stucchi RS, Vigani AG. Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors. Braz J Med Biol Res 2016;49:S0100-879X2016000700702. [PMID: 27356107 DOI: 10.1590/1414-431X20165300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
37 Powell D, Alpert A, Pacula RL. A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C. Health Aff (Millwood) 2019;38:287-94. [PMID: 30715966 DOI: 10.1377/hlthaff.2018.05232] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 13.5] [Reference Citation Analysis]
38 Wang XK, Liao XW, Yang CK, Liu ZQ, Han QF, Zhou X, Zhang LB, Deng T, Gong YZ, Huang JL, Huang R, Han CY, Yu TD, Su H, Ye XP, Peng T, Zhu GZ. Oncogene PLCE1 may be a diagnostic biomarker and prognostic biomarker by influencing cell cycle, proliferation, migration, and invasion ability in hepatocellular carcinoma cell lines. J Cell Physiol 2020;235:7003-17. [PMID: 32037547 DOI: 10.1002/jcp.29596] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
39 Beste LA, Zhang X, Su GL, Van T, Ioannou GN, Oselio B, Tincopa M, Liu B, Singal AG, Zhu J, Waljee AK. Adapted time-varying covariates Cox model for predicting future cirrhosis development performs well in a large hepatitis C cohort. BMC Med Inform Decis Mak 2021;21:347. [PMID: 34903225 DOI: 10.1186/s12911-021-01711-7] [Reference Citation Analysis]
40 Garbuzenko DV. [The role of antiviral therapy in the management of patients with liver cirrhosis associated with chronic HBV and HCV infection]. Vopr Virusol 2021;66:331-9. [PMID: 34738448 DOI: 10.36233/0507-4088-70] [Reference Citation Analysis]
41 Ladhani S, Ohri A, Wong RJ. Disparities in Hepatocellular Carcinoma Surveillance: Dissecting the Roles of Patient, Provider, and Health System Factors. Journal of Clinical Gastroenterology 2020;54:218-26. [DOI: 10.1097/mcg.0000000000001313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Possuelo LG, Perin D, Breunig PF, Schroeder DF, Allgayer MF, Darsie C, Carneiro M, Hermes V, Renner JDP. Hepatitis C: evaluation of outcomes and georeferencing of cases in Santa Cruz do Sul, Brazil, between 2002 and 2015. A cross-sectional study. Sao Paulo Med J 2018;136:109-15. [PMID: 29267536 DOI: 10.1590/1516-3180.2017.0169180917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
43 Agrawal B. Heterologous Immunity: Role in Natural and Vaccine-Induced Resistance to Infections. Front Immunol 2019;10:2631. [PMID: 31781118 DOI: 10.3389/fimmu.2019.02631] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
44 Lanini S, Ustianowski A, Pisapia R, Zumla A, Ippolito G. Viral Hepatitis. Infectious Disease Clinics of North America 2019;33:1045-62. [DOI: 10.1016/j.idc.2019.08.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
45 Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells 2020;9:E875. [PMID: 32260126 DOI: 10.3390/cells9040875] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 24.5] [Reference Citation Analysis]
46 Nakayama JY, Ho J, Cartwright E, Simpson R, Hertzberg VS. Predictors of progression through the cascade of care to a cure for hepatitis C patients using decision trees and random forests. Comput Biol Med 2021;134:104461. [PMID: 33975209 DOI: 10.1016/j.compbiomed.2021.104461] [Reference Citation Analysis]
47 Sanvisens A, Muñoz A, Bolao F, Zuluaga P, Farré M, Jarrin I, Tor J, Muga R. Do serum markers of liver fibrosis vary by HCV infection in patients with alcohol use disorder? Drug Alcohol Depend 2018;188:180-6. [PMID: 29778771 DOI: 10.1016/j.drugalcdep.2018.04.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
48 Barror S, Avramovic G, Oprea C, Surey J, Story A, Macías J, Cullen W, Crowley D, Horan A, Naughton AM, Iglesias M, Ianache I, Lazar S, Popa I, McHugh T, Menezes D, Tinago W, Lambert JS. HepCare Europe: a service innovation project. HepCheck: enhancing HCV identification and linkage to care for vulnerable populations through intensified outreach screening. A prospective multisite feasibility study. J Antimicrob Chemother 2019;74:v39-46. [PMID: 31782499 DOI: 10.1093/jac/dkz455] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
49 Marangon CG, de Bitencorte JT, Michita RT, Lunge VR, Dos Santos DC, Álvares-da-Silva MR, Simon D. Association between MICA rs2596542 Polymorphism with the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients. Pathol Oncol Res 2020;26:1519-25. [PMID: 31471884 DOI: 10.1007/s12253-019-00738-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Saab S, Viramontes MR, Chalifoux SL, Craw CJ, Ramirez SD, Bau SN, Arevalo DG, Saab EG, Saab CE, Craw CS, Estafanous A, Messiah R, Messiah W, El Kabany M. Hepatitis C Virus Prevalence in Egyptian Americans in Southern California. J Clin Gastroenterol 2018;52:55-9. [PMID: 28617761 DOI: 10.1097/MCG.0000000000000858] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Juanbeltz R, Castilla J, Martínez-Baz I, O'Leary A, Sarobe M, San Miguel R. Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population. Qual Life Res 2019;28:1477-84. [PMID: 30666549 DOI: 10.1007/s11136-019-02111-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
52 Gadiparthi C, Cholankeril G, Perumpail BJ, Yoo ER, Satapathy SK, Nair S, Ahmed A. Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates. World J Gastroenterol 2018; 24(3): 315-322 [PMID: 29391754 DOI: 10.3748/wjg.v24.i3.315] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
53 Zhou HJ, Cao J, Shi H, Naidoo N, Semba S, Wang P, Fan YF, Zhu SC. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China. Front Public Health 2021;9:779215. [DOI: 10.3389/fpubh.2021.779215] [Reference Citation Analysis]
54 Cholankeril G, Joseph-Talreja M, Perumpail BJ, Liu A, Yoo ER, Ahmed A, Goel A. Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents. J Clin Transl Hepatol 2017;5:363-7. [PMID: 29226102 DOI: 10.14218/JCTH.2017.00007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
55 Dotters-Katz SK, Kuller JA, Hughes BL; Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org. Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in pregnancy-updated guidelines: Replaces Consult Number 43, November 2017. Am J Obstet Gynecol 2021;225:B8-B18. [PMID: 34116035 DOI: 10.1016/j.ajog.2021.06.008] [Reference Citation Analysis]
56 Azevedo LA, Matte U, Silveira TR, Bonfanti JW, Bruch JP, Álvares-da-Silva MR. Effect of Vitamin D Serum Levels and GC Gene Polymorphisms in Liver Fibrosis Due to Chronic Hepatitis C. Ann Hepatol 2017;16:742-8. [PMID: 28809744 DOI: 10.5604/01.3001.0010.2748] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
57 Magri MC, Alvarez MSM, Iogi AA, Alves GM, Manchiero C, Dantas BP, Prata TVG, Nunes AKDS, Tengan FM. Study of CXCL9-11 gene polymorphisms in liver fibrosis among patients with chronic hepatitis C. Pathog Dis 2021;79:ftab007. [PMID: 33476381 DOI: 10.1093/femspd/ftab007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020. MMWR Recomm Rep. 2020;69:1-17. [PMID: 32271723 DOI: 10.15585/mmwr.rr6902a1] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 44.5] [Reference Citation Analysis]
59 Yang J, Zhang Y, Luo L, Meng R, Yu C. Global Mortality Burden of Cirrhosis and Liver Cancer Attributable to Injection Drug Use, 1990-2016: An Age-Period-Cohort and Spatial Autocorrelation Analysis. Int J Environ Res Public Health 2018;15:E170. [PMID: 29361804 DOI: 10.3390/ijerph15010170] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
60 Smith S, Honegger JR, Walker C. T-Cell Immunity against the Hepatitis C Virus: A Persistent Research Priority in an Era of Highly Effective Therapy. Cold Spring Harb Perspect Med 2021;11:a036954. [PMID: 32205413 DOI: 10.1101/cshperspect.a036954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
61 Chan K, Mangla N. Prevalence and risk factors of hepatitis C virus infection in the rural northeastern United States. Ann Hepatol 2021;:100576. [PMID: 34752949 DOI: 10.1016/j.aohep.2021.100576] [Reference Citation Analysis]
62 Eyster ME, Kong L, Li M, Schreibman IR. Long term survival in persons with hemophilia and chronic hepatitis C: 40 year outcomes of a large single center cohort. Am J Hematol 2016;91:E335-40. [PMID: 27214557 DOI: 10.1002/ajh.24427] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
63 Valiakou V, Eliadis P, Karamichali E, Tsitsilonis O, Koskinas J, Georgopoulou U, Foka P. Differential Expression of the Host Lipid Regulators ANGPTL-3 and ANGPTL-4 in HCV Infection and Treatment. Int J Mol Sci 2021;22:7961. [PMID: 34360721 DOI: 10.3390/ijms22157961] [Reference Citation Analysis]
64 Watts T, Lauver D, Sethi AK, Snedden T, Zahner S. Hepatitis C virus infections among people aged 15-44, United States, 2009-2018. Public Health Nurs 2021;38:167-75. [PMID: 32935390 DOI: 10.1111/phn.12808] [Reference Citation Analysis]
65 Essa S, Al-Attiyah R, Siddique I, Al-Nakib W. Modulation of Immune Cell Subsets by Hepatitis C Virus and Antiviral Therapy in Early Virological Response HCV Genotype 4-Infected Patients with Compensated Liver Disease. Med Princ Pract 2021;30:168-77. [PMID: 32966988 DOI: 10.1159/000511783] [Reference Citation Analysis]
66 Jovel J, Lin Z, O'keefe S, Willows S, Wang W, Zhang G, Patterson J, Moctezuma-Velázquez C, Kelvin DJ, Ka-Shu Wong G, Mason AL. A Survey of Molecular Heterogeneity in Hepatocellular Carcinoma. Hepatol Commun 2018;2:941-55. [PMID: 30094405 DOI: 10.1002/hep4.1197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
67 Ellwanger JH, Kaminski VL, Valverde-Villegas JM, Simon D, Lunge VR, Chies JAB. Immunogenetic studies of the hepatitis C virus infection in an era of pan-genotype antiviral therapies - Effective treatment is coming. Infect Genet Evol 2018;66:376-91. [PMID: 28811194 DOI: 10.1016/j.meegid.2017.08.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
68 Berbesi-Fernández DY, Segura-Cardona AM, Montoya-Velez LP, Santamaría AÁ. Use of injected heroin and risk of hepatitis C in three cities in Colombia. Rev Bras Epidemiol 2017;20:435-44. [PMID: 29160436 DOI: 10.1590/1980-5497201700030007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Salomon B, Krause PC, Dasa V, Shi L, Jones D, Chapple AG. The Impact of Hepatitis C and Liver Disease on Risk of Complications After Total Hip and Knee Arthroplasty: Analysis of Administrative Data From Louisiana and Texas. Arthroplast Today 2021;7:200-7. [PMID: 33553550 DOI: 10.1016/j.artd.2020.12.016] [Reference Citation Analysis]
70 Qureshi N, Tadesse M, Tran N, Henderson S. Establishing an Epidemiologic Profile of Hepatitis C Virus Infection at the Los Angeles County Jail. Public Health Rep 2021;136:726-35. [PMID: 33602004 DOI: 10.1177/0033354920988610] [Reference Citation Analysis]
71 Volesky KD, El-Zein M, Franco EL, Brenner DR, Friedenreich CM, Ruan Y; ComPARe Study Team. Estimates of the future burden of cancer attributable to infections in Canada. Prev Med 2019;122:118-27. [PMID: 31078165 DOI: 10.1016/j.ypmed.2019.04.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Estrada V, Sagastagoitia I. Hepatitis C is a risk factor for cardiovascular disease. Revista Clínica Española (English Edition) 2019;219:322-3. [DOI: 10.1016/j.rceng.2019.03.005] [Reference Citation Analysis]
73 Araújo RC, Bertol BC, César Dias F, Debortoli G, Almeida PH, Fernandes Souza F, Villanova MG, Ramalho LNZ, Candolo Martinelli AL, Cruz Castelli ÉD, Mendes Junior CT, Antonio Donadi E. HLA-E gene polymorphisms in chronic hepatitis C: Impact on HLA-E liver expression and disease severity. Hum Immunol 2021;82:177-85. [PMID: 33597096 DOI: 10.1016/j.humimm.2021.01.018] [Reference Citation Analysis]
74 Lanini S, Pisapia R, Capobianchi MR, Ippolito G. Global epidemiology of viral hepatitis and national needs for complete control. Expert Rev Anti Infect Ther 2018;16:625-39. [PMID: 30067107 DOI: 10.1080/14787210.2018.1505503] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
75 Ye D, Tang Y, Gu Y, Haleem H, Zhang L, Zhang Y, Xu C, Zhao J. Evaluation of the effectiveness of a pilot study of hospital-based hepatitis C epidemic surveillance. Medicine (Baltimore) 2019;98:e18334. [PMID: 31860986 DOI: 10.1097/MD.0000000000018334] [Reference Citation Analysis]
76 Uribe-Noguez LA, Mata-Marín JA, Ocaña-Mondragón A, Pompa-Mera EN, Ribas-Aparicio RM, Arroyo-Anduiza CI, Gomez-Torres ME, Chaparro-Sánchez A, Gaytán-Martínez J, Mauss S. Comparison of direct sequencing of the NS5B region with the Versant HCV genotype 2.0 assay for genotyping of viral isolates in Mexico. J Infect Chemother 2020;26:205-10. [PMID: 31537472 DOI: 10.1016/j.jiac.2019.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Reiser M, Wiebner B, Hirsch J; German Liver Foundation. Neural-network analysis of socio-medical data to identify predictors of undiagnosed hepatitis C virus infections in Germany (DETECT). J Transl Med 2019;17:94. [PMID: 30890175 DOI: 10.1186/s12967-019-1832-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
78 Sepulveda-Crespo D, Resino S, Martinez I. Hepatitis C virus vaccine design: focus on the humoral immune response. J Biomed Sci 2020;27:78. [PMID: 32631318 DOI: 10.1186/s12929-020-00669-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
79 Mori Ubaldini F, Stratta RJ, Nunez M. Delayed spontaneous hepatitis C virus elimination in a renal transplant patient following graft rejection. Transpl Infect Dis 2019;21:e13079. [PMID: 30882950 DOI: 10.1111/tid.13079] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
80 Bamias G, Pizarro TT, Cominelli F. Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab251. [PMID: 34904152 DOI: 10.1093/ibd/izab251] [Reference Citation Analysis]
81 Zhou S, Liang X, Wang N, Shao L, Yu W, Ding N, Zhang K, Liu M. Association of human platelet antigens polymorphisms with the levels of serum fibrosis marks in chronic hepatitis C patients. Transfus Apher Sci 2021;60:102967. [PMID: 33059995 DOI: 10.1016/j.transci.2020.102967] [Reference Citation Analysis]
82 Benítez-Gutiérrez L, Barreiro P, Labarga P, de Mendoza C, Fernandez-Montero JV, Arias A, Peña JM, Soriano V. Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin Pharmacother 2016;17:1215-23. [PMID: 27149603 DOI: 10.1080/14656566.2016.1182156] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
83 Zachou K, Arvaniti P, Gatselis NK, Azariadis K, Papadamou G, Rigopoulou E, Dalekos GN. Patients with Haemoglobinopathies and Chronic Hepatitis C: A Real Difficult to Treat Population in 2016? Mediterr J Hematol Infect Dis 2017;9:e2017003. [PMID: 28101309 DOI: 10.4084/MJHID.2017.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
84 Ellwanger JH, Kulmann-Leal B, Kaminski VL, Rodrigues AG, Bragatte MAS, Chies JAB. Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases. Virus Res 2020;286:198040. [PMID: 32479976 DOI: 10.1016/j.virusres.2020.198040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
85 Pourmarzi D, Smirnov A, Hall L, FitzGerald G, Rahman T. 'I'm over the moon!': patient-perceived outcomes of hepatitis C treatment. Aust J Prim Health 2020;26:319-24. [PMID: 32580867 DOI: 10.1071/PY20013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
86 Diniz KGD, Vieira DA, Colosimo EA, Coelho MPP, Bering T, Teixeira R, Correia MITD, Rocha GA, Silva LD. Derivation and validation of a simple anthropometric equation to predict fat-free mass in patients with chronic hepatitis C. Clin Nutr 2021;40:1281-8. [PMID: 32861484 DOI: 10.1016/j.clnu.2020.08.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
87 Adams LM, Balderson B, Packett BJ 2nd. Meeting the Challenge: Hepatitis C Virus and HIV Care Experiences Among HIV Specialty Providers. AIDS Patient Care STDS 2018;32:314-20. [PMID: 30067406 DOI: 10.1089/apc.2018.0006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
88 Luna-Cuadros MA, Chen HW, Hanif H, Ali MJ, Khan MM, Lau DTY. Risk of hepatocellular carcinoma after hepatitis C virus cure. World J Gastroenterol 2022; 28(1): 96-107 [DOI: 10.3748/wjg.v28.i1.96] [Reference Citation Analysis]
89 Bastos JCS, Padilla MA, Caserta LC, Miotto N, Vigani AG, Arns CW. Hepatitis C virus: Promising discoveries and new treatments. World J Gastroenterol 2016; 22(28): 6393-6401 [PMID: 27605875 DOI: 10.3748/wjg.v22.i28.6393] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
90 Yurlov KI, Masalova OV, Kisteneva LB, Khlopova IN, Samokhvalov EI, Malinovskaya VV, Parfyonov VV, Shuvalov AN, Kushch AA. Human Herpesviruses Increase the Severity of Hepatitis. Biology (Basel) 2021;10:483. [PMID: 34072365 DOI: 10.3390/biology10060483] [Reference Citation Analysis]
91 Lambert JS, Murtagh R, Menezes D, O'Carroll A, Murphy C, Cullen W, McHugh T, Avramovic G, Tinago W, Van Hout MC. 'HepCheck Dublin': an intensified hepatitis C screening programme in a homeless population demonstrates the need for alternative models of care. BMC Infect Dis 2019;19:128. [PMID: 30732573 DOI: 10.1186/s12879-019-3748-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
92 Marincu I, Bratosin F, Curescu M, Suciu O, Turaiche M, Cerbu B, Vidican I. Direct-Acting Antiviral Use for Genotype 1b Hepatitis C Patients with Associated Hematological Disorders from Romania. Medicina (Kaunas) 2021;57:986. [PMID: 34577909 DOI: 10.3390/medicina57090986] [Reference Citation Analysis]
93 Benitez TM, Fernando SM, Amini C, Saab S. Geographically Focused Collocated Hepatitis C Screening and Treatment in Los Angeles's Skid Row. Dig Dis Sci 2020;65:3023-31. [PMID: 31974916 DOI: 10.1007/s10620-020-06073-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
94 Abutaleb A, Almario JA, Alghsoon S, Yoon JA, Gheysens K, Kottilil S, Wilson E. Higher Levels of Fibrosis in a Cohort of Veterans with Chronic Viral Hepatitis are Associated with Extrahepatic Cancers. J Clin Exp Hepatol 2021;11:195-200. [PMID: 33746444 DOI: 10.1016/j.jceh.2020.08.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
95 Kishk R, Mandour M, Elprince M, Salem A, Nemr N, Eida M, Ragheb M. Pattern and interpretation of hepatitis B virus markers among pregnant women in North East Egypt. Braz J Microbiol. 2020;51:593-600. [PMID: 31677078 DOI: 10.1007/s42770-019-00174-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
96 Rosenberg ES, Hall EW, Sullivan PS, Sanchez TH, Workowski KA, Ward JW, Holtzman D. Estimation of State-Level Prevalence of Hepatitis C Virus Infection, US States and District of Columbia, 2010. Clin Infect Dis 2017;64:1573-81. [PMID: 28449115 DOI: 10.1093/cid/cix202] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
97 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
98 Daniel Moore J, Galbraith J, Humphries R, Havens JR. Prevalence of Hepatitis C Virus Infection Identified From Nontargeted Screening Among Adult Visitors in an Academic Appalachian Regional Emergency Department. Open Forum Infect Dis 2021;8:ofab374. [PMID: 34381848 DOI: 10.1093/ofid/ofab374] [Reference Citation Analysis]
99 Juanbeltz R, Martínez-Baz I, San Miguel R, Goñi-Esarte S, Cabasés JM, Castilla J. Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients. PLoS One 2018;13:e0205277. [PMID: 30300395 DOI: 10.1371/journal.pone.0205277] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
100 Volesky KD, El-Zein M, Franco EL, Brenner DR, Friedenreich CM, Ruan Y; ComPARe Study Team. Cancers attributable to infections in Canada. Prev Med 2019;122:109-17. [PMID: 31078164 DOI: 10.1016/j.ypmed.2019.03.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
101 Kaya M, Nakamura K, Sugiyama K, Kinae A, Yamaguchi H, Ukita H, Odagiri K, Ujiie C, Kato J, Kageyama F, Nagura M, Matsushita K, Sugiue K, Ishida H, Endo S, Suzuki T. Retrospective multicentre study on the effectiveness of first-line direct-acting antivirals against hepatitis C virus genotype-1. J Clin Pharm Ther 2022. [PMID: 35229326 DOI: 10.1111/jcpt.13624] [Reference Citation Analysis]
102 Mar J, Martínez-Baz I, Ibarrondo O, Juanbeltz R, San Miguel R, Casado I, O'Leary A, Castilla J. Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments. Expert Rev Gastroenterol Hepatol 2019;13:699-708. [PMID: 28946785 DOI: 10.1080/17474124.2017.1383155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]